Effect of infused L-threo-3,4-dihydroxyphenylserine on adrenergic activity in patients with familial amyloid polyneuropathy
- PMID: 6772451
- DOI: 10.1007/BF00570160
Effect of infused L-threo-3,4-dihydroxyphenylserine on adrenergic activity in patients with familial amyloid polyneuropathy
Abstract
L-threo-3,4-dihydroxyphenylserine (DOPS), an immediate precursor amino acid of (-)-norepinephrine, was used as a pharmacological tool to investigate the pathophysiology of the peripheral sympathetic nervous system in Type 1 familial amyloid polyneuropathy. Patients with the well-established disorder showed an enhanced pressor response to L-threo-DOPS under conditions that produced no change in normal subjects. While octopamine induced a brisk pressor response, L-threo-DOPS produced a slow and prolonged change in blood pressure, with a marked concomitant increase in urinary excretion of norepinephrine. A slight increase in urinary excretion of total metanephrine was observed in both groups, but there was no significant increase in serum dopamine-beta-hydroxylase activity. Since infusion of dilute norepinephrine into patients also produced a markedly hypersensitive response, the characteristic pressor response to L-threo-DOPS was indicative of denervation supersensitivity of adrenergic receptors to norepinephrine formed enzymatically from L-threo-DOPS.
Similar articles
-
Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy.Eur J Clin Pharmacol. 1982;23(5):463-8. doi: 10.1007/BF00605999. Eur J Clin Pharmacol. 1982. PMID: 6818040
-
Studies of neurocirculatory effects of long-term L-threo-3,4-dihydroxyphenylserine administration in a patient with familial amyloidotic polyneuropathy.Acta Neurol Scand. 1988 May;77(5):409-13. doi: 10.1111/j.1600-0404.1988.tb05927.x. Acta Neurol Scand. 1988. PMID: 3137768
-
Diuretic effects of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) in anesthetized rats.Jpn J Pharmacol. 1990 Mar;52(3):431-9. doi: 10.1254/jjp.52.431. Jpn J Pharmacol. 1990. PMID: 2110272
-
The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors.J Neural Transm Suppl. 2006;(70):477-84. doi: 10.1007/978-3-211-45295-0_71. J Neural Transm Suppl. 2006. PMID: 17017570 Review.
-
[Development of L-threo-DOPS, a norepinephrine precursor amino acid].Yakugaku Zasshi. 1994 Nov;114(11):823-46. doi: 10.1248/yakushi1947.114.11_823. Yakugaku Zasshi. 1994. PMID: 7853146 Review. Japanese.
Cited by
-
Memory effect of DL-threo-3,4-dihydroxyphenylserine (DOPS) in human Korsakoff's disease.Psychopharmacology (Berl). 1988;95(2):250-4. doi: 10.1007/BF00174518. Psychopharmacology (Berl). 1988. PMID: 3137605 Clinical Trial.
-
DL-threo-DOPS as a precursor of noradrenaline.Naunyn Schmiedebergs Arch Pharmacol. 1985 Nov;331(2-3):202-8. doi: 10.1007/BF00634239. Naunyn Schmiedebergs Arch Pharmacol. 1985. PMID: 3937060
-
Acute pandysautonomia: mass spectrometric and histopathological studies of the sympathetic nervous system during long term L-threo-3,4-dihydroxyphenylserine treatment.J Neurol Neurosurg Psychiatry. 1996 Jul;61(1):99-102. doi: 10.1136/jnnp.61.1.99. J Neurol Neurosurg Psychiatry. 1996. PMID: 8676171 Free PMC article.
-
Uptake of L-threo-dihydroxyphenylserine into human brain synaptosomes.J Neural Transm. 1987;70(1-2):51-61. doi: 10.1007/BF01252508. J Neural Transm. 1987. PMID: 3117973
-
Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy.Eur J Clin Pharmacol. 1982;23(5):463-8. doi: 10.1007/BF00605999. Eur J Clin Pharmacol. 1982. PMID: 6818040
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
